All the news Showing 10 of 87 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Fatty liver disease common in people living with HIV and hepatitis B Keith Alcorn / 30 September 2020 Around one in three people with HIV and hepatitis B had fatty liver disease and one in ten had liver damage, US researchers from the Hepatitis B Research Network report in Clinical ... Diabetes raises the risk of liver damage in people with HIV Keith Alcorn / 21 September 2020 Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had non-alcoholic steatohepatitis (NASH) and 39 of 116 had stage F3 or F4 fibrosis, and advanced ... Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... Fatty liver disease affects one in four in Europe, study estimates Keith Alcorn / 07 September 2020 Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ... Novel methods of non-invasive testing for non-alcoholic fatty liver disease EASL / 28 August 2020 ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive